Efficacy and Tolerance of Glatiramer Acid (Copaxone) on Long-Term Use: 10 Years of Experience at the Moscow City Multiple Sclerosis Center
We summarize here 10 years of experience of using glatiramer acetate (Copaxone) in 74 patients with active remitting multiple sclerosis (MS). Significant decreases in the frequency of disease exacerbation over all 10 years were noted. Disease severity on the EDSS was stable and increased significantly only by the tenth year of observations. Positive stable clinical dynamics were independent of disease severity at the moment of treatment initiation. Tolerance of glatiramer acetate was good, allowing us to come close to controlling the course of MS – 64.8% of patients had no more than one exacerbation in 10 years, while 71.6% showed no or minimal progression of disease (up to 1 point on the EDSS scale). These observations lead to the conclusion that 10 years of treatment with Copaxone allows disease development to be controlled in many patients.
Keywordsmultiple sclerosis treatment glatiramer acetate prolonged observations
Unable to display preview. Download preview PDF.
- 1.A. N. Boiko, M. V. Davydovskaya, T. L. Demina, et al., “Results of prolonged use of Copaxone and Betaferon at the Moscow City Multiple Sclerosis Centre: assessment of efficacy and treatment compliance,” Zh. Nevrol. Psikhiat., No. 3, 101–110 (2006).Google Scholar
- 2.A. N. Boiko, M. V. Davydovskaya, T. L. Demina, et al., “Experience of the prolonged use of MSDMD in daily neurological practice: results of 5-year treatment of multiple sclerosis patients at the MCMSC,” Zh. Nevrol. Psikhiat., Spec. Iss., Multiple Sclerosis, No. 4, 84–94 (2007).Google Scholar
- 3.E. I. Gusev and A. N. Boiko, Multiple Sclerosis: from Studies of Immunopathogenesis to New Treatment Methods [in Russian], Gubernskaya Meditsina, Moscow (2001).Google Scholar
- 4.T. V. Sidorenko, A. N. Boiko, and E. I. Gusev, “Compliance with long-term treatment with agents altering the course of multiple sclerosis (MSDMD),” Zh. Nevrol. Psikhiat., 7, No. 2, 107–113 (2009).Google Scholar
- 5.C. C. Ford, “Long-term experience with current disease-modifying drugs in multiple sclerosis,” J. Neurol., 253, Suppl. 6, 37–44 (2006).Google Scholar
- 9.J. Noserworthy, D. Miller, and A. Compston, “Disease-modifying treatments in multiple sclerosis,” in: McAlpine’s Multiple Sclerosis, A. Compston et al. (eds.), Churchill Livingstone, Elsevier (2006), pp. 729–802.Google Scholar